Residency · Residency · Emergency Medicine

Beta-Blocker and Calcium Channel Blocker Overdose

Overview

Epidemiology

Cardiovascular drug toxicity is a leading cause of poisoning fatality. Both beta-blocker and calcium channel blocker overdoses can produce profound bradycardia, hypotension, and cardiogenic shock. Sustained-release formulations cause delayed and prolonged toxicity, and co-ingestion is common and worsens the prognosis.

Key Pharmacologic Differences

Beta-blockers block beta-1 (cardiac) and beta-2 (pulmonary, vascular) adrenergic receptors. Calcium channel blockers block L-type calcium channels, but two subclasses behave differently. The dihydropyridines (amlodipine, nifedipine) primarily cause peripheral vasodilation with less cardiac depression at therapeutic doses, though they cause cardiogenic shock in overdose. The non-dihydropyridines (verapamil, diltiazem) produce negative inotropy, chronotropy, and dromotropy, making them more dangerous in overdose.

Beta-Blocker Toxicity

High-Risk Agents

Propranolol is the most lethal beta-blocker in overdose because it possesses sodium channel blocking activity (causing QRS widening), is highly lipophilic (allowing CNS penetration with seizures and coma), and has membrane-stabilizing activity. Sotalol is dangerous because of potassium channel blockade that prolongs the QTc and can cause torsades de pointes. Carvedilol has combined alpha and beta blockade, producing profound vasodilation. Atenolol and metoprolol are beta-1 selective, but this selectivity is lost in overdose.

Clinical Presentation

The cardiovascular hallmark is bradycardia, along with hypotension, AV block, and cardiogenic shock. Metabolic derangements include hypoglycemia from impaired glycogenolysis and gluconeogenesis, which is especially dangerous in children and diabetics, as well as hyperkalemia. Lipophilic agents, particularly propranolol, cause CNS effects including seizures, coma, and delirium. ECG findings may include sinus bradycardia, AV block, wide QRS (propranolol), prolonged QTc (sotalol), and junctional rhythm. Bronchospasm can occur in susceptible patients.

Management

Management begins with the ABCs: IV access, continuous cardiac monitoring, and transcutaneous pacing pads placed on standby. Atropine at 0.5 to 1 mg IV may be tried but is often ineffective in severe overdose because the mechanism is not purely vagal. Glucagon is the traditional first-line antidote, given as a 3 to 5 mg IV bolus that may be repeated, followed by a 2 to 5 mg per hour infusion if effective. It bypasses beta-receptor blockade by activating adenylate cyclase through the glucagon receptor. However, it is often insufficient alone, and side effects include nausea and vomiting (pretreat with ondansetron) and hyperglycemia.

High-dose insulin (HDI) at 1 unit/kg bolus followed by 1 to 10 units/kg per hour infusion enhances cardiac glucose utilization and is increasingly used as primary therapy. It must be given with dextrose (D50 bolus, then D10 to D25 infusion), with glucose monitored every 15 to 30 minutes initially and potassium supplemented as needed. Vasopressors, either norepinephrine or epinephrine, are used for refractory hypotension, often at high doses. Calcium has limited role in pure beta-blocker toxicity but is more useful in CCB overdose. Lipid emulsion therapy (20 percent intralipid, 1.5 mL/kg bolus followed by 0.25 mL/kg per minute infusion) should be considered for lipophilic beta-blocker toxicity (propranolol) that is refractory to other therapies. Sodium bicarbonate is indicated for propranolol-induced QRS widening from sodium channel blockade. VA-ECMO is the last resort for refractory cardiogenic shock and may serve as a bridge to recovery.

Calcium Channel Blocker Toxicity

Clinical Presentation

The cardiovascular effects include bradycardia, hypotension, AV block, junctional rhythm, and cardiogenic shock. Verapamil and diltiazem produce more pronounced bradycardia and cardiac depression, while dihydropyridines may cause reflex tachycardia early before progressing to cardiovascular collapse. A key metabolic distinction from beta-blocker toxicity is that CCBs cause hyperglycemia (rather than hypoglycemia) because they inhibit insulin release from pancreatic beta cells. The degree of hyperglycemia is a marker of toxicity severity. ECG findings include bradycardia, prolonged PR interval, AV block, and junctional rhythm, with the QRS typically remaining narrow unless cardiac depression is severe. GI effects include ileus and nausea. Sustained-release CCBs (verapamil SR, diltiazem ER) have a delayed onset of toxicity that can take hours and a prolonged course lasting 24 to 48 or more hours.

Management

Atropine at 0.5 to 1 mg IV is usually ineffective for severe CCB toxicity. Calcium directly antagonizes CCB effects and is given as calcium chloride 10 percent (1 to 2 grams IV via central line, as it is a vesicant) or calcium gluconate 10 percent (3 to 6 grams IV, which can be given peripherally but contains less elemental calcium). Calcium boluses can be repeated every 10 to 15 minutes for up to 3 to 4 doses, and a calcium infusion may be started. Ionized calcium should be monitored, targeting twice the normal level.

High-dose insulin euglycemic therapy (HIET) is considered first-line for severe CCB toxicity. Regular insulin is given as a 1 unit/kg IV bolus followed by 1 to 10 units/kg per hour infusion. The mechanism involves enhanced myocardial glucose uptake and utilization, producing a positive inotropic effect that works independently of calcium channels. Dextrose is given as a D50 bolus of 25 to 50 grams followed by a D10 to D25 infusion, titrated to maintain euglycemia. Potassium must be monitored every 30 minutes initially and supplemented aggressively because insulin drives potassium intracellularly. The hemodynamic effect of HIET may take 15 to 45 minutes to manifest, so it should not be abandoned prematurely. Dosing protocols vary between institutions, with some toxicologists advocating doses up to 10 units/kg per hour in refractory cases.

Second-line therapies include vasopressors (norepinephrine as the first-line vasopressor, along with epinephrine and vasopressin), often at high doses. Glucagon at 3 to 5 mg IV bolus followed by 2 to 5 mg per hour infusion is less reliable in CCB than in beta-blocker toxicity. Lipid emulsion therapy (20 percent intralipid, 1.5 mL/kg bolus followed by 0.25 mL/kg per minute for 60 minutes) is generally reserved as rescue therapy when other measures fail, as the evidence for its use in BB and CCB toxicity is limited to case reports and animal data. It may also interfere with laboratory testing by causing lipemia. Methylene blue at 1 to 2 mg/kg IV is an emerging rescue therapy for refractory vasoplegic shock, working by inhibiting nitric oxide synthase. Transcutaneous or transvenous pacing may be attempted for symptomatic bradycardia or heart block, but it may fail to capture in severe myocardial depression.

For refractory or last-resort situations, VA-ECMO provides mechanical circulatory support as a bridge to recovery but requires a specialized center. Intra-aortic balloon pump is less commonly used than ECMO.

Decontamination

Whole bowel irrigation is strongly recommended for sustained-release preparations, using polyethylene glycol solution at 1 to 2 liters per hour via nasogastric tube until clear rectal effluent is produced. Activated charcoal is useful if given within 1 to 2 hours of an immediate-release ingestion and may be useful later for sustained-release formulations. Syrup of ipecac should not be used because of the risk of aspiration and vagal stimulation.

Monitoring and Disposition

All intentional beta-blocker and CCB ingestions require ICU admission with continuous cardiac monitoring. Sustained-release preparations require observation for a minimum of 24 hours even if the patient is initially asymptomatic. Immediate-release formulations with no symptoms after 6 hours of observation may be safe for medical clearance, provided a sustained-release formulation has been excluded.

Distinguishing BB from CCB Overdose

<image>A treatment algorithm flowchart for beta-blocker and calcium channel blocker overdose. Starting with "Suspected BB or CCB overdose with hemodynamic instability" branching to two parallel pathways. BB pathway: atropine (usually ineffective) → glucagon 3-5 mg IV bolus → HDI (1 unit/kg bolus, then 1-10 units/kg/hr with dextrose and K+ monitoring) → vasopressors (norepinephrine/epinephrine) → ILE for lipophilic agents → consider ECMO. CCB pathway: atropine (usually ineffective) → calcium (CaCl 1-2 g or CaGluc 3-6 g, repeat q10-15 min) → HDI (same protocol) → vasopressors → glucagon → ILE → methylene blue for vasoplegic shock → consider ECMO. A shared box at the top notes: WBI for sustained-release formulations, IV fluids, transcutaneous pacing pads on standby. A key differentiating box highlights: BB = hypoglycemia, CCB = hyperglycemia.</image>

<image>A diagram illustrating the mechanism of high-dose insulin euglycemic therapy (HIET). Panel 1: Normal myocardial metabolism — the heart uses free fatty acids (60-70%) and glucose (20-30%) as energy substrates. Panel 2: CCB/BB toxicity — calcium channel/beta-receptor blockade impairs calcium-dependent contractility and metabolic pathways; the stressed myocardium shifts toward glucose as the preferred fuel. Panel 3: HIET mechanism — high-dose insulin promotes myocardial glucose uptake through GLUT4 transporter upregulation, improving inotropy independent of calcium channels or beta receptors. The diagram shows the insulin dosing protocol (1 unit/kg bolus → 1-10 units/kg/hr) with concurrent dextrose infusion and potassium monitoring requirements.</image>

<image>An ECG comparison panel showing typical findings in BB and CCB overdose. Panel 1: Sinus bradycardia with normal QRS (typical of CCB or cardioselective BB). Panel 2: Wide QRS complex tachycardia from propranolol overdose (sodium channel blockade). Panel 3: QTc prolongation with sotalol overdose. Panel 4: High-degree AV block with junctional escape from verapamil overdose. Each ECG strip is labeled with the offending agent and the key abnormality highlighted.</image>

Clinical Pearls

Hyperglycemia in cardiovascular drug overdose points to a calcium channel blocker, while hypoglycemia points to a beta-blocker, and this metabolic distinction helps guide therapy. High-dose insulin is first-line for severe CCB toxicity, but its effect on myocardial contractility takes 15 to 45 minutes to develop, so it should not be abandoned prematurely. Glucagon is the traditional beta-blocker antidote but is often insufficient alone and should be combined with high-dose insulin and vasopressors. Propranolol is the most dangerous beta-blocker in overdose because of its sodium channel blockade (requiring bicarbonate for QRS widening), lipophilicity (causing seizures), and membrane-stabilizing activity. Sustained-release CCB and beta-blocker ingestions can present with delayed toxicity hours after ingestion, so observation for at least 24 hours is essential. Whole bowel irrigation is critical for sustained-release formulations, which can form concretions and cause prolonged absorption. VA-ECMO is the last resort for refractory cardiogenic shock, and early contact with an ECMO-capable center is essential. Calcium is useful in CCB toxicity but has a limited role in pure beta-blocker overdose.

References

• St-Onge M, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol. 2014;52:926-944.
• Engebretsen KM, et al. High-dose insulin therapy in beta-blocker and calcium channel blocker poisoning. Clin Toxicol. 2011;49:277-283.
• Graudins A, et al. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81:453-461.
• Weinberg GL. Lipid emulsion infusion: resuscitation for local anesthetic and other drug overdose. Anesthesiology. 2012;117:180-187.
• Levine M, et al. Assessment of hyperinsulinemia-euglycemia therapy (HIET) in cardiovascular drug overdose. Clin Toxicol. 2020;58:930-938.

Read this lecture as Markdown